Food and Drug Administration (FDA) Research 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Profiling lecanemab as a treatment option for Alzheimer's disease
Expert Rev Neurother. 2024 Apr 3:1-9. doi: 10.1080/14737175.2024.2333970. Online ahead of print.ABSTRACTINTRODUCTION: In July 2023, the U.S. Food and Drug Administration (FDA) granted full approval to lecanemab for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. Considering the limited treatment options for AD, the approval of lecanemab offers hope and opens the door for other disease-modifying therapies in the pipeline.AREAS COVERED: In this review, the authors summarize the FDA treatment guidelines, other anti-amyloid agents, and drug information relevant to prescrib...
Source: Expert Review of Neurotherapeutics - April 3, 2024 Category: Neurology Authors: Emily R Schiller Bret David Silverglate George T Grossberg Source Type: research
